Mr. Hochman has over 20 years of healthcare, entrepreneurial and venture capital experience. He currently serves as the Chairman of the Board of Directors and Chief Executive Officer of Orchestra BioMed, a therapeutic device company focused on the development and commercialization of high impact, data-driven, transformational solutions for targeted high value unmet medical needs. Since 2007, Mr. Hochman has been Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employs a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value.
Mr. Hochman currently serves as a board member of two non-profit organizations: The Citizens Committee for New York City and The Mollie Parnis Livingston Foundation.
He graduated with honors from the University of Michigan.
In addition to being the Managing Director of Jacobs Investment Company, LLC, Mr. Jacobs serves on the boards of Next Generation Technologies and Fallbrook Technologies, Inc. and is also Chairman of Nutrina, Ltd., a biotechnology company focused on bioactive supplements for infant formulas.
Mr. Jacobs is actively involved with education and philanthropy, serving as Chairman of the Board of Trustees of High Tech High in San Diego and Chair of the Dean’s Advisory Council for Social Sciences at the University of California, San Diego.
He received his Bachelor of Arts degree in Management Science from the University of California, San Diego.
Mr. Korangy is a seasoned executive with broad expertise, having more than 20 years of experience in investing and operating roles across a wide range of industries. He currently serves as the President and CEO of BVI Medical, Inc., a leading global developer, manufacturer and marketer of surgical devices for the ophthalmic marketplace. Prior to this, he served as the CFO and Chief Strategy Officer of BVI. Prior to his appointment at BVI, Mr. Korangy was a senior executive at Novartis Group AG (NYSE: NVS), where he served as the Global Head of Corporate Finance. At Novartis he ran multiple international geographies for the Alcon Division. Prior to joining Novartis in 2010, Mr. Korangy served as a Managing Director at The Blackstone Group (NYSE: BX), where he spent approximately 15 years in the firm's restructuring and private equity businesses. He currently serves on the Board of Directors of BVI Holdings Ltd and The Hain Celestial Group (NASDAQ: HAIN) and has previously served on several other public and private corporate boards.
Mr. Moran has served as Chief Executive Officer since October 1, 2018. Prior to joining the Company, from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) (“ConvaTec”), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Coviden plc (“Coviden”), an Irish-headquartered global health care products company and manufacturer of medical devices and supplies. While at Coviden, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. Mr. Moran was selected as a director because of his broad commercial experience and leadership in the medical technology sector.
Dr. Samuel Nussbaum brings expertise across the spectrum of healthcare. Having served as the Chief Medical Officer of WellPoint/Anthem and, previously, Executive Vice President for BJC HealthCare, he has executive experience in population health, care management, data analytics, provider contracting, and medical and pharmacy policy and contracting. As a professor and clinical leader at Harvard Medical School and Massachusetts General Hospital he has led basic science research, drug discovery, clinical studies, teaching and patient care.
Dr. Nussbaum serves as Chair of a public-private work group established by the Department of Health and Human Services to develop the framework for alternate payment models to enhance patient-centered care and reduce waste in healthcare. Dr. Nussbaum brings deep knowledge of the drivers of healthcare costs, including specialty pharmaceuticals, and has crafted strategies and applied solutions to better manage these costs for Medicare, Medicaid, and commercial health plans. He has led public health initiatives to improve diabetes care, childhood obesity and hospital safety and quality.
Dr. Nussbaum received his undergraduate degree from New York University and his MD from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology and metabolism at Harvard Medical School and Massachusetts General Hospital. Dr. Nussbaum is a Professor of Clinical Medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.
With 30 years of experience in the medical device industry, Mr. Pomeranz brings a strong track record of success in both start-ups and in large multinational organizations.
Prior to joining Motus GI in 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems. Other previous positions include serving as a Vice President at Cordis, a Johnson & Johnson company, and in senior leadership roles at Cardiac Pathways Corporations and Cardiovascular Imaging Systems, both acquired by Boston Scientific Corporation.
Mr. Pomeranz earned a MSc in Biomedical Engineering from the University of Miami, a BS in Mechanical Engineering from Union College and currently holds over 40 patents.
Mr. Pruden joins the Motus GI board having most recently served as Executive Vice President and Worldwide Chairman for the Johnson & Johnson ("J&J"; NYSE: JNJ) Medical Devices group. Over the course of his 32-year career at J&J, Mr. Pruden held numerous senior leadership positions across both the medical devices and pharmaceutical sectors. As the Worldwide Chairman of the Medical Device group, he led a global business where new technologies, global expansion and focus on the patient were keys to success.
During his career at J&J, Mr. Pruden led a large global business with a significant portion of sales coming from outside of the United States including a strong focus on emerging markets. He has a broad background in technology and pharmaceutical innovation and has been involved in numerous M&A transactions at J&J. Mr. Pruden also helped lead the J&J strategic collaboration with Google that was established for the advancement of surgical robotics. He has extensive experience in portfolio management including two large divestitures (Cordis Corporation and Codman Neurosurgery) and exits of non-strategic businesses, quality and compliance, as well as global regulatory experience. Mr. Pruden earned his bachelor's degree in Finance from Rider University and served on the Board of Trustees of Rider University from 2011-2015.
Mr. Sherman is a Managing Partner of Orchestra Medical Ventures, an investment firm that employs an innovative strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and superior investor returns. He is also Chief Technical Officer of Accelerated Technologies, Inc. (ATI) and CEO and Director of Caliber Therapeutics, Inc., and FreeHold Surgical, Inc.
In addition to serving as a Director of Caliber Therapeutics, Inc., Mr. Sherman holds that same role with Freehold Surgical, Inc.
He earned his Bachelor of Science degree in Bioengineering from the University of California, San Diego and has authored over 60 US patents with over 75 published applications.